First human evidence of age reversal
Researchers at a major academic medical center conducted the trial on 108 adults with HIV-associated lipohypertrophy, a condition involving abnormal fat distribution. Participants received weekly semaglutide injections or a placebo. Those on the drug showed measurable reversal in several epigenetic aging markers, including DNA methylation patterns linked to cellular senescence. The findings represent the first randomized, placebo-controlled evidence in humans that a GLP-1 receptor agonist may influence biological aging.
Inflammation reduction key to effect
The study authors attribute the anti-aging effect primarily to semaglutide's ability to reduce chronic inflammation and improve fat distribution. The inflammatory system showed the most pronounced improvement, with biological aging markers in that category delayed by nearly five years. Brain aging markers also improved notably. The drug works by mimicking a hormone that regulates appetite and blood sugar, but its anti-inflammatory properties appear to drive the longevity benefit.
Implications for age-related disease prevention
While the study focused on people with HIV, researchers believe the findings may generalize to broader populations. Semaglutide is already prescribed to millions for diabetes and weight management. If the anti-aging effect is confirmed in larger, longer trials, GLP-1 drugs could become a tool for preventing age-related conditions including cardiovascular disease, cognitive decline, and certain cancers. Larger phase 3 trials are being planned.